Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced voting results from its annual and special meeting of shareholders held on Sept. 22, 2026. A total of 46,452,598 common shares were represented, accounting for 63.58% of outstanding shares as of the record date, according to the company's press release. Shareholders appointed Zeifmans LLP as auditor, approved setting the board at eight directors, and elected Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall, and Eric So as directors.
In a move that underscores a strategic pivot, shareholders also approved changing the company's legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1. This follows the adoption of the Helus Pharma business name on Jan. 5. The name change reflects the company's anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company. For more details on Helus Pharma, visit Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP).
The rebranding is significant because it aligns with Helus Pharma's evolving focus on proprietary novel serotonergic agonists (NSAs) – synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and to learn more, visit www.helus.com.
The annual meeting results and the name change are important because they signal shareholder confidence in the company's leadership and strategic direction. The election of a diverse board, including experts like Dr. Eric Hoskins and Dr. Freda Lewis-Hall, brings valuable experience as Helus Pharma navigates the transition to commercialization. The legal name change is not merely cosmetic; it represents a clear rebranding that aligns the company's identity with its commercial ambitions in the mental health space. As Helus Pharma advances its pipeline, including the Phase 3 program for HLP003, the successful meeting outcomes provide a stable governance foundation. This news matters to investors and patients alike, as it highlights a company poised to potentially deliver innovative treatments for depression and anxiety, conditions that affect millions worldwide.
The announcement was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions via InvestorWire and other services. For full terms of use and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
